Patient-derived tumor xenografts of lung squamous cell carcinoma alter long non-coding RNA profile but not responsiveness to cisplatin

Lung squamous cell carcinoma (LSCC), the second most common type of lung cancer, has received limited attention. Patient-derived tumor xenografts (PDTXs) are useful preclinical models to reproduce the diverse heterogeneity of cancer, but it is important to identify potential variations during their establishment. A total of 18 PDTXs were established from 37 the surgical specimens and 16 were serially passaged to third generation. Second- and third-generation xenografts had a faster growth rate in mice. The tumor implantation success rate was associated with poorer differentiation, larger tumor volume and higher expression of Ki-67. The xenografts largely retained histological and key immunophenotypic features (including p53, p63, cytokeratin5/6, and E-cadherin). However, increased Ki-67 expression was identified in partial xenografts. Long non-coding RNA (lncRNA) and mRNA expression in third-generation xenografts differed from that of matched primary tumors. Gene Ontology and pathway analysis showed that mRNAs involved in cell cycle, and metabolism regulation were generally upregulated in xenografts, while those associated with immune responses were typically downregulated. Furthermore, the responses of xenografts to cisplatin were consistent with clinical outcome. In the present study, PDTXs of SCC were successfully established, and closely resembled their original tumor regarding their immunophenotype and response to cisplatin. Overall, PDTXS of LSCC altered the lncRNA profile and increased the proliferative activity of cancer cells, whilst retaining responsiveness to cisplatin.

[1]  Gang Liu,et al.  TFPI2AS1, a novel lncRNA that inhibits cell proliferation and migration in lung cancer , 2017, Cell cycle.

[2]  P. Fortina,et al.  Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis , 2017, Journal of Translational Medicine.

[3]  Shuhan Sun,et al.  The MBNL3 splicing factor promotes hepatocellular carcinoma by increasing PXN expression through the alternative splicing of lncRNA-PXN-AS1 , 2017, Nature Cell Biology.

[4]  J. McPherson,et al.  Molecular heterogeneity of non‐small cell lung carcinoma patient‐derived xenografts closely reflect their primary tumors , 2017, International journal of cancer.

[5]  Ming Sun,et al.  LncRNA HOXA11-AS Promotes Proliferation and Invasion of Gastric Cancer by Scaffolding the Chromatin Modification Factors PRC2, LSD1, and DNMT1. , 2016, Cancer research.

[6]  M. Tsao,et al.  Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma , 2016, Clinical Cancer Research.

[7]  Xuefei Shi,et al.  Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer , 2016, Scientific Reports.

[8]  D. Gisselsson,et al.  Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours. , 2016, Cancer letters.

[9]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[10]  G. Mills,et al.  Proteomic Characterization of Head and Neck Cancer Patient–Derived Xenografts , 2015, Molecular Cancer Research.

[11]  M. Frydenberg,et al.  Establishment of primary patient‐derived xenografts of palliative TURP specimens to study castrate‐resistant prostate cancer , 2015, The Prostate.

[12]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[13]  K. Shaw,et al.  Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. , 2015, Cancer letters.

[14]  K. Junker,et al.  Therapieinduzierte Tumorregression und Regressionsgrading bei Lungenkarzinomen , 2014, Der Pathologe.

[15]  J. Steitz,et al.  The Noncoding RNA Revolution—Trashing Old Rules to Forge New Ones , 2014, Cell.

[16]  M. Rubin,et al.  High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. , 2014, Cancer research.

[17]  S. Lam,et al.  Genetic alterations defining NSCLC subtypes and their therapeutic implications. , 2013, Lung cancer.

[18]  Sarah Geisler,et al.  RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts , 2013, Nature Reviews Molecular Cell Biology.

[19]  Nicholas T. Ingolia,et al.  Ribosome Profiling Provides Evidence that Large Noncoding RNAs Do Not Encode Proteins , 2013, Cell.

[20]  J. Pignon,et al.  Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Philippe Dessen,et al.  Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer , 2012, Clinical Cancer Research.

[22]  Anne Vincent-Salomon,et al.  Molecular profiling of patient-derived breast cancer xenografts , 2012, Breast Cancer Research.

[23]  Thomas J. Smith,et al.  2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Tsao,et al.  The Ability to Form Primary Tumor Xenografts Is Predictive of Increased Risk of Disease Recurrence in Early-Stage Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[25]  E. Felip,et al.  Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Howard Y. Chang,et al.  Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis , 2010, Nature.

[27]  S. Lam,et al.  Patient-Derived First Generation Xenografts of Non–Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy , 2010, Clinical Cancer Research.

[28]  S. Patnaik,et al.  Lung cancer xenografting alters microRNA profile but not immunophenotype. , 2009, Biochemical and biophysical research communications.

[29]  D. Spector,et al.  Long noncoding RNAs: functional surprises from the RNA world. , 2009, Genes & development.

[30]  K. Garber.  From human to mouse and back: 'tumorgraft' models surge in popularity. , 2009, Journal of the National Cancer Institute.

[31]  Michael Becker,et al.  Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers , 2008, Clinical Cancer Research.

[32]  J. Pignon,et al.  Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Qinzhong Chen,et al.  Establishment and characterization of human urothelial cancer xenografts in severe combined immunodeficient mice , 2006, International journal of urology : official journal of the Japanese Urological Association.

[34]  R. Kerbel.  Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived—But They Can Be Improved , 2003, Cancer biology & therapy.

[35]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[36]  M. Christian,et al.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.

[37]  R. Perez-soler,et al.  Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  D. Spector,et al.  Molecular and Cellular Pathobiology The Noncoding RNA MALAT 1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells , 2013 .

[39]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[40]  K. Junker.  [Therapy-induced tumor regression]. , 2004, Der Pathologe.